Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrijn Grupping

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro activities of candidate microbicides against cell-associated HIVPhilippe Selhorst, Katrijn Grupping, Thomas Bourlet, et al.
Human Vaccines & Immunotherapeutics|January 10, 2017
Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trialOlivier Godeaux, Martina Kovac, Daniel Shu, et al.
Retrovirology|December 17, 2009
Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodiesTessa Dieltjens, Leo Heyndrickx, Betty Willems, et al.
Retrovirology|May 4, 2012
MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiencyKatrijn Grupping, Philippe Selhorst, Johan Michiels, et al.
AIDS Research and Human Retroviruses|November 6, 2009
HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodiesTessa Dieltjens, Nathalie Loots, Katleen Vereecken, et al.
Retrovirology|February 5, 2013
M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 sheddingPhilippe Selhorst, Katrijn Grupping, Tommy Tong, et al.
The Journal of Infectious Diseases|October 14, 2017
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster VaccineKatrijn Grupping, Laura Campora, Martine Douha, et al.
Human Vaccines & Immunotherapeutics|June 4, 2019
Evaluation of two frailty indices, with practical application in a vaccine clinical trialDesmond Curran, Melissa K Andrew, Myron J Levin, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 13, 2020
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older AdultsKenneth E Schmader, Myron J Levin, Michael Chen, et al.
The Journal of Infectious Diseases|October 14, 2017
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or OlderTino F Schwarz, Naresh Aggarwal, Beate Moeckesch, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro activities of candidate microbicides against cell-associated HIVPhilippe Selhorst, Katrijn Grupping, Thomas Bourlet, et al.
Human Vaccines & Immunotherapeutics|January 10, 2017
Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trialOlivier Godeaux, Martina Kovac, Daniel Shu, et al.
Retrovirology|December 17, 2009
Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodiesTessa Dieltjens, Leo Heyndrickx, Betty Willems, et al.
Retrovirology|May 4, 2012
MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiencyKatrijn Grupping, Philippe Selhorst, Johan Michiels, et al.
AIDS Research and Human Retroviruses|November 6, 2009
HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodiesTessa Dieltjens, Nathalie Loots, Katleen Vereecken, et al.
Retrovirology|February 5, 2013
M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 sheddingPhilippe Selhorst, Katrijn Grupping, Tommy Tong, et al.
The Journal of Infectious Diseases|October 14, 2017
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster VaccineKatrijn Grupping, Laura Campora, Martine Douha, et al.
Human Vaccines & Immunotherapeutics|June 4, 2019
Evaluation of two frailty indices, with practical application in a vaccine clinical trialDesmond Curran, Melissa K Andrew, Myron J Levin, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|June 13, 2020
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older AdultsKenneth E Schmader, Myron J Levin, Michael Chen, et al.
The Journal of Infectious Diseases|October 14, 2017
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or OlderTino F Schwarz, Naresh Aggarwal, Beate Moeckesch, et al.
Pageof 2